EVAX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.650

Open

3.080

VWAP

3.44

Vol

49.14K

Mkt Cap

29.86M

Low

3.080

Amount

168.88K

EV/EBITDA(TTM)

--

Total Shares

8.34M

EV

14.13M

EV/OCF(TTM)

--

P/S(TTM)

--

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Show More

Events Timeline

(ET)

2026-03-05

09:40:00

Evaxion Secures Over $30 Million in New Capital for 2025

2026-03-05

09:40:00

Evaxion Reports Q4 Revenue of $0, CEO Highlights Future Growth

2026-03-05

09:40:00

Evaxion's 2026 Strategy Includes Expanding AI-Immunology

2026-01-13 (ET)

2026-01-13

08:30:00

Evaxion Expands AI-Immunology Platform to Autoimmune Diseases

2025-12-19 (ET)

2025-12-19

07:10:00

Evaxion Retains Global Rights to EVX-B2 as MSD Declines Option

2025-12-07 (ET)

2025-12-07

13:20:00

Evaxion Announces New Data on EVX-04 Vaccine Showing Strong T-Cell Responses

News

seekingalpha

03-06seekingalpha

Evaxion A/S Reports Strong Q4 2025 Earnings and Strategic Developments

seekingalpha

03-05seekingalpha

Evaxion Biotech Reports FY EPS Beat Expectations

Newsfilter

03-05Newsfilter

Evaxion A/S Provides 2025 Business and Financial Update

Yahoo Finance

03-02Yahoo Finance

Evaxion to Report 2025 Financial Results on March 5

Benzinga

2025-12-19Benzinga

Evaxion Looks for New Partner for Gonorrhea Vaccine Following Merck's Withdrawal

Globenewswire

2025-12-19Globenewswire

Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option

3 Analyst Rating

Wall Street analysts forecast EVAX stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

10.00

Averages

12.33

High

16.00

Current: 0.000

Low

10.00

Averages

12.33

High

16.00

Lake Street

Buy

downgrade

$11 -> $9

AI Analysis

2026-03-09

New

Reason

Lake Street

Price Target

$11 -> $9

AI Analysis

2026-03-09

New

downgrade

Buy

Reason

Lake Street lowered the firm's price target on Evaxion Biotech to $9 from $11 and keeps a Buy rating on the shares. The firm updated the outlook for potential licensing deals after Evaxion reported Q4 results and provided a corporate update.

JonesResearch

NULL -> Buy

initiated

$10

2026-03-09

New

Reason

JonesResearch

Price Target

$10

2026-03-09

New

initiated

NULL -> Buy

Reason

JonesResearch assumed coverage of Evaxion Biotech with a Buy rating and $10 price target. The firm says the company uses its AI-driven platform to design novel oncology and infectious disease vaccines. Evaxion's "promising" melanoma asset is likely to attract strategic interest, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EVAX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Evaxion A/S (EVAX.O) is -9.06, compared to its 5-year average forward P/E of -4.83. For a more detailed relative valuation and DCF analysis to assess Evaxion A/S's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.83

Current PE

-9.06

Overvalued PE

0.50

Undervalued PE

-10.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.45

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.08

Undervalued EV/EBITDA

-2.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

11.77

Current PS

31.43

Overvalued PS

28.62

Undervalued PS

-5.09

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Bullish penny stock tomorrow

Intellectia · 13 candidates

Market Cap: <= 750.00MRegion: USPrice: $0.50 - $5.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 70One Day Predict Return: >= 2.0%Macd: bullish

Ticker

Name

Market Cap$

Edesa Biotech Inc

11.35M

Carparts.Com Inc

46.18M

Cumberland Pharmaceuticals Inc

61.32M

BioNexus Gene Lab Corp

5.97M

Rani Therapeutics Holdings Inc

164.04M

Dyadic International Inc

30.38M

high growth stocks trading under $5

Intellectia · 184 candidates

Price: <= $5.00Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

TDH Holdings Inc

10.74M

ReTo Eco-Solutions Inc

2.60M

Iovance Biotherapeutics Inc

1000.00M

Loop Industries Inc

61.87M

Evaxion A/S

26.61M

Onconetix Inc

1.65M

con rentabilidad alta a corto plazo

Intellectia · 61 candidates

Price: <= $20.00Quarter Revenue Yoy Growth: >= 20.0%Quarter Eps Yoy Growth: >= 15.0%Relative Vol: >= 1.50

Ticker

Name

Market Cap$

Rhinebeck Bancorp Inc

134.53M

Blaize Holdings Inc

255.60M

Xilio Therapeutics Inc

40.33M

Lexicon Pharmaceuticals Inc

566.90M

Immunitybio Inc

6.82B

MDB Capital Holdings LLC

33.86M

best performing medical stocks under 30usd

Intellectia · 5 candidates

Price: <= $30.00Net Margin: >= 10.00Pe Ttm: <= 25Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

ACADIA Pharmaceuticals Inc

4.53B

Amicus Therapeutics Inc

4.44B

ADMA Biologics Inc

4.13B

Catalyst Pharmaceuticals Inc

2.97B

Evaxion A/S

34.86M

Whales Holding EVAX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Evaxion A/S (EVAX) stock price today?

The current price of EVAX is 3.58 USD — it has increased 16.23

What is Evaxion A/S (EVAX)'s business?

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

What is the price predicton of EVAX Stock?

Wall Street analysts forecast EVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVAX is12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Evaxion A/S (EVAX)'s revenue for the last quarter?

Evaxion A/S revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is Evaxion A/S (EVAX)'s earnings per share (EPS) for the last quarter?

Evaxion A/S. EPS for the last quarter amounts to USD, decreased -100.00

How many employees does Evaxion A/S (EVAX). have?

Evaxion A/S (EVAX) has 46 emplpoyees as of March 11 2026.

What is Evaxion A/S (EVAX) market cap?

Today EVAX has the market capitalization of 29.86M USD.